Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4034977 | 0.91 | CASP3 (0.58) | CASP3KMT2AMEN1RAB9AHTT | |
| SCHEMBL6543874 | 0.81 | FADS1 (0.50) | KMT2AP2RX1 | |
| SCHEMBL395950 | 0.78 | TRPV1 (0.59) | CASP3RAB9AHTTGAASMN1; SMN2 | |
| SCHEMBL5627831 | 0.78 | MEN1 (0.55) | CASP3KMT2AMEN1RAB9AHTT | |
| SCHEMBL397661 | 0.76 | MEN1 (0.63) | CASP3KMT2AMEN1RAB9AHTT | |
| SCHEMBL11735609 | 0.75 | RAB9A (0.58) | CASP3KMT2AMEN1RAB9AHTT | |
| SCHEMBL12857582 | 0.74 | CASP3 (0.91) | CASP3KMT2AMEN1RAB9AHTT | |
| SCHEMBL13442870 | 0.74 | CASP3 (1.00) | CASP3KMT2AMEN1RAB9AHTT | |
| SCHEMBL12553629 | 0.73 | MEN1 (0.74) | CASP3KMT2AMEN1RAB9AHTT | |
| SCHEMBL995085 | 0.73 | GAA (0.77) | KMT2AMEN1RAB9AHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392680-B1 | SELECTIVE ANTHRANILAMIDE PYRIDINE AMIDES AS INHIBITORS OF VEGFR-2 AND VEGFR-3 | BAYER SCHERING PHARMA AG (DE) | 2009-07-22 | — | — | EP | disclosed |
| US-20040254185-A1 | Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-12-16 | — | — | US | disclosed |
| CN-1518546-A | Selective anthranilamide picolinamides as VEGRF-2 and VEGFR-3 inhibitors | ���ֹɷݹ�˾ | 2004-08-04 | — | — | CN | disclosed |
| US-20040039019-A1 | Selected anthranilaminde pyridinamides and their use as pharmaceutical agents | SCHERING AG (DE) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039019-A1 | Selected anthranilaminde pyridinamides and their use as pharmaceutical agents | KDR, FLT1, FLT4 | CASP3 896/4885KMT2A 3109/4885MEN1 2641/4885 |
| US-20040254185-A1 | Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 | FLT4, KDR, FLT1 | CASP3 542/4885KMT2A 1262/4885MEN1 3913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.